Authors

Latest:

Dr. Mason on Progress Made in Resectable Stage III Lung Cancer

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.

David P. Steensma, MD

Latest:

Dr. Steensma on the Utility of Venetoclax in MDS

David P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.

David P. Steensma, MD, Dana-Farber Cancer Institute

David Parker, PhD

Latest:

CMS Decision Helps Unlock the Potential of Next-Generation Testing

Provisions to a final national coverage determination that expanded coverage for next-generation sequencing tests have implications for any NGS-based cancer test provided to Medicare beneficiaries and will inevitably influence the coverage thinking of commercial payers.

David Pearlstone, MD

Latest:

Dr. Pearlstone Discusses Mammogram Deterrents

Dr. David Pearlstone from John Theurer Cancer Center Discusses Mammogram Deterrents

David Piccioni, MD, PhD

Latest:

Dr. Piccioni on Tumor Profiles of Brain Metastases

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

David Planchard, MD, PhD

David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy. He is also president of the International Center for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.

Latest:

Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC

David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

David Planchard, MD, PhD

David Polsky, MD, PhD

Latest:

Dr. Polsky on the Association Between ctDNA and Survival in Melanoma

David Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.

David R. Gandara

Latest:

Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

David R. Gandara, MD

Latest:

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

Dr Gandara discusses the optimal use of liquid biopsy for patients with NSCLC and available treatment options for patients with KRAS-mutant NSCLC.

David R. Gandara, MD, UC Davis

David R. Gandara, MD, UC Davis Comprehensive Cancer Center

David R. Spigel, MD

David R. Spigel, MD is chief scientific officer at SCRI, wherhe oversees all scientific aspects of SCRI’s clinical trial program.

Latest:

Dr Spigel on a 14-Gene Assay for Clarifying the Benefit of Adjuvant Chemo in NSCLC

David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.

David R. Spigel, MD, Sarah Cannon Research Institute

Latest:

Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial

David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer

David R. Wise, MD, PhD

Latest:

Dr Wise on the Impact of Genetic Testing on Patient Outcomes in Prostate Cancer

David R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.

David Reardon, MD

Latest:

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

David Reardon, MD, Dana-Farber Cancer Institute

Latest:

Rapid Readouts: Results of the SCOUT and NAVIGATE Trials

David A. Reardon, MD, presents slides, shown at the 2021 American Society of Clinical Oncology Annual Meeting, from the phase 2 NAVIGATE basket trial and the phase 1/2 SCOUT trial in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion–positive primary central nervous system (CNS) tumors treated with larotrectinib with or without prior therapy.

David Rimm MD, PhD

Latest:

Dr Rimm on the Effect of Inaccurate HER2 IHC Testing for Patients With Breast Cancer

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.

David Ritchie, MD, PhD

Latest:

Dr. Ritchie on Immunological Recovery With Venetoclax and Ibrutinib in MCL

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.